Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 14.40
DXCM's Cash to Debt is ranked higher than
83% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. DXCM: 14.40 )
DXCM' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 14.4

Equity to Asset 0.72
DXCM's Equity to Asset is ranked higher than
80% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. DXCM: 0.72 )
DXCM' s 10-Year Equity to Asset Range
Min: -0.63   Max: 0.92
Current: 0.72

-0.63
0.92
F-Score: 7
Z-Score: 55.95
M-Score: -3.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -11.21
DXCM's Operating margin (%) is ranked higher than
58% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. DXCM: -11.21 )
DXCM' s 10-Year Operating margin (%) Range
Min: -2272.81   Max: -18.06
Current: -11.21

-2272.81
-18.06
Net-margin (%) -11.61
DXCM's Net-margin (%) is ranked higher than
60% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.99 vs. DXCM: -11.61 )
DXCM' s 10-Year Net-margin (%) Range
Min: -2147.42   Max: -18.63
Current: -11.61

-2147.42
-18.63
ROE (%) -28.38
DXCM's ROE (%) is ranked higher than
56% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. DXCM: -28.38 )
DXCM' s 10-Year ROE (%) Range
Min: -60327.45   Max: -37
Current: -28.38

-60327.45
-37
ROA (%) -20.03
DXCM's ROA (%) is ranked higher than
55% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. DXCM: -20.03 )
DXCM' s 10-Year ROA (%) Range
Min: -178.43   Max: -26.08
Current: -20.03

-178.43
-26.08
ROC (Joel Greenblatt) (%) -77.34
DXCM's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. DXCM: -77.34 )
DXCM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3333.88   Max: -100
Current: -77.34

-3333.88
-100
Revenue Growth (%) 38.30
DXCM's Revenue Growth (%) is ranked higher than
97% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. DXCM: 38.30 )
DXCM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 103.1
Current: 38.3

0
103.1
EBITDA Growth (%) -25.50
DXCM's EBITDA Growth (%) is ranked higher than
54% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. DXCM: -25.50 )
DXCM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 0.6
Current: -25.5

0
0.6
EPS Growth (%) -24.30
DXCM's EPS Growth (%) is ranked higher than
56% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. DXCM: -24.30 )
DXCM' s 10-Year EPS Growth (%) Range
Min: -40.1   Max: 37.1
Current: -24.3

-40.1
37.1
» DXCM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DXCM Guru Trades in Q4 2013

Paul Tudor Jones 8,059 sh (New)
Jim Simons 557,543 sh (+168.9%)
Ron Baron 1,357,357 sh (-0.86%)
Mario Gabelli 74,000 sh (-1.33%)
RS Investment Management 477,381 sh (-23.17%)
» More
Q1 2014

DXCM Guru Trades in Q1 2014

Steven Cohen 13,332 sh (New)
RS Investment Management 496,081 sh (+3.92%)
Ron Baron 1,354,112 sh (-0.24%)
Mario Gabelli 71,000 sh (-4.05%)
Paul Tudor Jones 7,198 sh (-10.68%)
Jim Simons 380,843 sh (-31.69%)
» More
Q2 2014

DXCM Guru Trades in Q2 2014

Joel Greenblatt 8,033 sh (New)
RS Investment Management 538,660 sh (+8.58%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Ron Baron 1,348,572 sh (-0.41%)
Mario Gabelli 70,500 sh (-0.7%)
» More
Q3 2014

DXCM Guru Trades in Q3 2014

Joel Greenblatt Sold Out
Ron Baron 1,345,322 sh (-0.24%)
Mario Gabelli 66,000 sh (-6.38%)
RS Investment Management 433,460 sh (-19.53%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out $35.35 - $45.89 $ 56.8538%0
Joel Greenblatt 2014-06-30 New Buy$29.68 - $41.95 $ 56.8561%8033
George Soros 2013-09-30 Sold Out 0.02%$21.78 - $29.19 $ 56.85124%0
George Soros 2013-03-31 New Buy0.02%$13.59 - $17.05 $ 56.85274%100000
Ron Baron 2012-12-31 New Buy0.11%$12.3 - $14.95 $ 56.85325%1250000
George Soros 2011-09-30 Sold Out 0.0025%$10.3 - $15.66 $ 56.85338%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DexCom Inc

Top Insider Sells Highlight: Dexcom Inc.
CEO, 10% Owner of Dexcom Inc (DXCM) Terrance H Gregg sold 23,893 shares on 08/21/2014 at an average price of $44.36. The total transaction amount was $1,059,893. Read more...

Ratios

vs
industry
vs
history
P/B 37.90
DXCM's P/B is ranked higher than
51% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. DXCM: 37.90 )
DXCM' s 10-Year P/B Range
Min: 3.88   Max: 209.25
Current: 37.9

3.88
209.25
P/S 18.80
DXCM's P/S is ranked lower than
52% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. DXCM: 18.80 )
DXCM' s 10-Year P/S Range
Min: 6.36   Max: 1058.5
Current: 18.8

6.36
1058.5
PFCF 815.10
DXCM's PFCF is ranked higher than
73% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 57.37 vs. DXCM: 815.10 )
DXCM' s 10-Year PFCF Range
Min: 578.57   Max: 812.14
Current: 815.1

578.57
812.14
EV-to-EBIT -167.89
DXCM's EV-to-EBIT is ranked lower than
57% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.42 vs. DXCM: -167.89 )
DXCM' s 10-Year EV-to-EBIT Range
Min: -167.6   Max: -1.6
Current: -167.89

-167.6
-1.6
Current Ratio 3.04
DXCM's Current Ratio is ranked higher than
78% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. DXCM: 3.04 )
DXCM' s 10-Year Current Ratio Range
Min: 1.96   Max: 23.47
Current: 3.04

1.96
23.47
Quick Ratio 2.69
DXCM's Quick Ratio is ranked higher than
82% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. DXCM: 2.69 )
DXCM' s 10-Year Quick Ratio Range
Min: 1.82   Max: 23.47
Current: 2.69

1.82
23.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 142.13
DXCM's Price/Net Cash is ranked higher than
86% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DXCM: 142.13 )
DXCM' s 10-Year Price/Net Cash Range
Min: 4.94   Max: 166
Current: 142.13

4.94
166
Price/Net Current Asset Value 71.07
DXCM's Price/Net Current Asset Value is ranked higher than
79% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DXCM: 71.07 )
DXCM' s 10-Year Price/Net Current Asset Value Range
Min: 4.94   Max: 207
Current: 71.07

4.94
207
Price/Tangible Book 40.04
DXCM's Price/Tangible Book is ranked higher than
57% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.44 vs. DXCM: 40.04 )
DXCM' s 10-Year Price/Tangible Book Range
Min: 4.7   Max: 154.75
Current: 40.04

4.7
154.75
Price/Median PS Value 1.29
DXCM's Price/Median PS Value is ranked higher than
70% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. DXCM: 1.29 )
DXCM' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 46.83
Current: 1.29

0.55
46.83
Earnings Yield (Greenblatt) -0.60
DXCM's Earnings Yield (Greenblatt) is ranked higher than
61% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. DXCM: -0.60 )
DXCM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -0.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:DC4.Germany,
The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company's SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
Top Insider Sells Highlight: Dexcom Inc. Aug 22 2014 
DexCom Reports $1 Million Insider Buy Mar 12 2013 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2010 
DexCom Inc. Reports Operating Results (10-Q) May 05 2010 
DexCom Inc. Reports Operating Results (10-Q) Nov 04 2009 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2009 
DexCom Inc. Reports Second Quarter 2009 Financial Results Aug 03 2009 
DexCom Inc. (DXCM) CEO Terrance H Gregg buys 20,000 Shares May 14 2009 
DexCom Inc. Reports Operating Results (10-Q) May 06 2009 
DexCom Inc. (DXCM) CEO Terrance H Gregg buys 50,000 Shares Mar 17 2009 

More From Other Websites
DexCom CEO Terry Gregg Explains 50% YTD Stock Leap, Plans for 2015 Dec 03 2014
DexCom to Present at Oppenheimer 25th Annual Healthcare Conference Dec 03 2014
DexCom to Present at Oppenheimer 25th Annual Healthcare Conference Dec 03 2014
DEXCOM INC Files SEC form 8-K/A, Change in Directors or Principal Officers Nov 25 2014
DexCom to Present at 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
DexCom Announces Appointment of Mark G. Foletta as Board Member Nov 19 2014
DEXCOM INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Nov 19 2014
DexCom Announces Appointment of Mark G. Foletta as Board Member Nov 19 2014
DEXCOM INC Financials Nov 14 2014
DexCom Scales 52-Week High on Product Pipeline Strength Nov 11 2014
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge Nov 10 2014
Strength Seen in DexCom (DXCM): Stocks Gains 14.1% Nov 10 2014
10-Q for DexCom, Inc. Nov 08 2014
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session Nov 07 2014
DexCom, Inc. Reports Third Quarter 2014 Financial Results Nov 06 2014
DexCom misses 3Q profit forecasts Nov 06 2014
DexCom misses 3Q profit forecasts Nov 06 2014
DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 06 2014
DexCom, Inc. Reports Third Quarter 2014 Financial Results Nov 06 2014
FDA Approves Dexcom Software with Artificial Pancreas Algorithm Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK